ROSA is going to be a disaster...

Discussion in 'Zimmer' started by anonymous, Jan 25, 2019 at 11:07 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    FDA cleared this morning, I guess. 6 months late and how are we supposed to sell this against MAKO? Tell everyone it’s cheaper? Is that it? Our sales manager is saying that the plan from ZB is to offer it to existing customers and target ASC facilities with value proposition. My doc sent me a picture of him standing next to it out in Toronto and the thing is the size of a Mini Cooper. How the hell are we going to wheel it through the doors at your avg Surgery Ctr?

    And why in the fuck would I want to talk my docs into using this....to double the tq time on my existing knee cases?

    Warsaw whiffs....again.

    But hey, at least we’re not Depuy, right.
     

  2. anonymous

    anonymous Guest

    You better learn to sell it or you will eventually loose business to mako. I would kill to have that.
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    How does Robotic TKA work without implants??
     
  5. anonymous

    anonymous Guest

    Been losing business to Mako since Stryker bought them. Give us a robot that actually competes, please.

    Rosa is a joke.
     
  6. anonymous

    anonymous Guest

    A robot is not going to keep your Attune BP from falling out onto the floor in a revision....
     
  7. anonymous

    anonymous Guest

    Doesn’t Rosa just place an existing 4:1 cutting block on the femur - then cut just like a regular manual TKA?
    Mako uses no 4:1 blocks - just a saw. The saw stays within preplanned boundaries and does not damage existing soft tissue.
    Stryker is light years ahead in this technology.
     
  8. anonymous

    anonymous Guest

    ROSA will only help to keep mako/stryker out of existing Zimmer accounts. It will be cheaper than mako but still pretty expensive to place a cutting block!
     
  9. anonymous

    anonymous Guest

    Stryker and Smith and Nephew have robots in OR and now were expected to sell this monster that adds nothing more then the other systems? Isn’t smith nephew an open platform also? Blue belt team was the pissed off mako team that left.... who made Rosa?
     
  10. anonymous

    anonymous Guest

    Yep. Way behind in technology and launch.
    ‘Disaster’ is appropriate
     
  11. anonymous

    anonymous Guest

    Rosa is just meant to maintain a level of competitiveness not increase sales.
     
  12. anonymous

    anonymous Guest

    Rosa is going to be great for Spine.
     
  13. anonymous

    anonymous Guest

    What you dumb ass Z aholes dont know and are too stupid to know is the makos price point will never be able to compete in the asc Navio has a steller year 150% to quota all in asc and in asc where Mako is strong in the hosp
    U dumb f s should sell something Z is not used too and go after the asc esp if
    Mako is in ur area!
    Most of mako is
    Marketing so piggy back their hospital based business and win where the business is going
    But that takes sales ability and not
    Simply Z consultant sellinguse your fucking heads
     
  14. anonymous

    anonymous Guest

    This was a really long way of saying that we sell inferior tech to ASCs at a lower price point, and we don’t sell outcomes...just marketing. Sounds like a SN a rep just got back from his National sales meeting, if that company can even afford to have one these days....

    Navio and Rosa are basically the same thing....and there’s a reason why MAKO is 96% of the Robotic Total Joint Market and Navio is 3%.

    Both platforms are 5+ years away from being able to compete with the functionality of Mako, if they ever will. It’s going to be difficult to bring Navio head to head with a doc that has used Mako in his or her hospital and win that ASC business, regardless of the difference in price point. Stryker will just respond to that competition by offering ProForma financing, which will capture nearly 100% of the implant business at that ASC. Those ASCs that cant comply with volume metrics aren’t worth chasing anyway.

    In short, you guys are fucked until you develop some technology that actually competes. It is what it is.
     
  15. anonymous

    anonymous Guest

    SN national sales meeting in February dipshit.
     
  16. anonymous

    anonymous Guest

    Out off that whole paragraph you come back with that? Game is over kids, Stryker is reloading on Mako before we even fire a shot. Shoulder docs are being pestered about mako now, apparently a whole new platform is coming for that now.
     
  17. anonymous

    anonymous Guest

    If only mako was an open platform....... they would dominate robotics... The blue belt team will get good market share based off that mistake alone. Mako shot themselves in the foot with that one. As we all know this is all just a marketing scam for hospitals to use anyways. No real competent surgeon wants to waste time on robotics during a case. If anyone sells a robot expect implant prices to fall with that sell. End up doing twice the work with robotics for same amount of money in the end.... ask stryker reps how mako and teir 1 pricing is going for them.... lol
     
  18. anonymous

    anonymous Guest

    How many makos are going to be needed when the upper extremity guys want in? Let’s see, per robot, we can do 3 cases per day, in the same room...one knee, one hip, and one shoulder. Dr. X with his shoulder case goes last. Scheduled at 3, starts at 6 PM with graveyard crew. Let’s just use it for the marketing brochure and hang some lead on it.
     
  19. anonymous

    anonymous Guest

    Lol. Mako cost a million bucks. SN is a quarter of that. What’s Rosa gonna cost?
     
  20. anonymous

    anonymous Guest

    Rosa made for Spine..... joints should have been free software for hospitals after robotics for Spine purchase.